pegs1, look at the link below. Last year 21 extremely ill COVI-19 patients with severe comorbidity problems were treated with Aviptadil. Seventeen of those patients (72%) survived through 28 days post treatment whereas only 4 of 24 (17%) equally sick patients lived through the same period of time.
The patients in the current trial all started on ventilators but wee less sick than the group mentioned above and have the advantage of having more recently fallen ill, at a time when the treatment has been getting better.
In such patients Aviptadil is probably not going to have a dramatic effect of greatly reducing the death because the number of deaths in this less severely ill SOC arm is most likely going to be small even after the 60 days on trial.
When compared to SOC, Aviptadil most likely will shorten the days of hospitalization and improve the patients' condition more rapidly. In my opinion that is worth a lot and I expect that the treatment will be approved by the FDA.
I believe that the company also does not expect Aviptadil to have a statistically significant effect in reducing the death rate and therefore the potential reduction of mortality has now been redesigned as one of the secondary endpoints.
Market Data 
Markets 
AI
